A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results

被引：95

作者：

Wohl, David ^{[1
]}

Oka, Shinichi ^{[2
]}

Clumeck, Nathan ^{[3
]}

Clarke, Amanda ^{[4
]}

Brinson, Cynthia ^{[5
]}

Stephens, Jeffrey ^{[6
]}

Tashima, Karen ^{[7
]}

Arribas, Jose R. ^{[8
]}

Rashbaum, Bruce ^{[9
]}

Cheret, Antoine ^{[10
]}

Brunetta, Jason ^{[11
]}

Mussini, Cristina ^{[12
]}

Tebas, Pablo ^{[13
,14
]}

Sax, Paul E. ^{[15
,16
,17
]}

Cheng, Andrew ^{[18
]}

Zhong, Lijie ^{[18
]}

Callebaut, Christian ^{[18
]}

Das, Moupali ^{[18
]}

Fordyce, Marshall ^{[18
]}

机构：

[1] Univ N Carolina, Dept Med, CB 7030,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA

[2] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[3] CHU St Pierre Univ Hosp Brussels, Dept Infect Dis, Brussels, Belgium

[4] Brighton & Sussex Univ Hosp NHS Trust, Elton John Ctr, Brighton, E Sussex, England

[5] Cent Texas Clin Res, Austin, TX USA

[6] Mercer Univ, Sch Med, Dept Internal Med, Macon, GA 31207 USA

[7] Brown Univ, Miriam Hosp, Alpert Med Sch, Providence, RI USA

[8] Hosp Univ La Paz, IdiPAZ, Internal Med Serv, Infect Dis Unit, Madrid, Spain

[9] Capital Ctr Travel & Trop Med, Washington, DC USA

[10] Ctr Hosp Tourcoing Descartes Univ, Necker Hosp, Le Kremlin Bicetre Hosp, AP HP,Infect Dis Unit,Internal Med Unit, Paris, France

[11] Univ Toronto, Dept Family & Community Med, Maple Leaf Res, Med, Toronto, ON M5S 1A1, Canada

[12] Univ Modena & Reggio Emilia, Clin Malattie Infett & Tropicali, Modena, Italy

[13] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

[14] Univ Penn, Perelman Sch Med, Ctr AIDS Res, Philadelphia, PA 19104 USA

[15] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA

[16] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA

[17] Harvard Univ, Sch Med, Boston, MA USA

[18] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 01期

关键词：

tenofovir alafenamide; integrase inhibitor; randomized controlled trial; HIV; bone mineral density; renal safety; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EFAVIRENZ; THERAPY; DENSITY; SAFETY;

D O I：

10.1097/QAI.0000000000000940

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In 2 double-blinded Phase 3 trials, 1733 antiretroviral-naive participants were randomized to tenofovir alafenamide (TAF), a tenofovir prodrug versus tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 96 weeks, 86.6% in the TAF arm and 85.2% in the TDF arm had HIV-1 RNA <50 c/mL [difference 1.5%; (95% CI: -1.8% to 4.8%)]. With TAF, there are smaller declines in bone mineral density and more favorable changes in proteinuria, albuminuria, and tubular proteinuria, and no cases of proximal tubulopathy compared with 2 for TDF. These longer-term data support E/C/F/TAF as a safe, welltolerated, and durable regimen for initial HIV-1 treatment.

引用

页码：58 / 64

页数：7

共 50 条

[21] Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1
Negredo, Eugenia
Clotet, Bonaventura
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 929 - 934
[22] Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
Mills, Anthony
Crofoot, Gordon, Jr.
McDonald, Cheryl
Shalit, Peter
Flamm, Jason A.
Gathe, Joseph, Jr.
Scribner, Anita
Shamblaw, David
Saag, Michael
Cao, Huyen
Martin, Hal
Das, Moupali
Thomas, Anne
Liu, Hui C.
Yan, Mingjin
Callebaut, Christian
Custodio, Joseph
Cheng, Andrew
McCallister, Scott
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 69 (04) : 439 - 445
[23] The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
Wang, Huilian
Lu, Xi
Yang, Xudong
Xu, Nan
MEDICINE, 2016, 95 (41)
[24] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Orkin, Chloe
DeJesus, Edwin
Ramgopal, Moti
Crofoot, Gordon
Ruane, Peter
LaMarca, Anthony
Mills, Anthony
Vandercam, Bernard
de Wet, Joseph
Rockstroh, Jurgen
Lazzarin, Adriano
Rijnders, Bart
Podzamczer, Daniel
Thalme, Anders
Stoeckle, Marcel
Porter, Danielle
Liu, Hui C.
Cheng, Andrew
Quirk, Erin
SenGupta, Devi
Cao, Huyen
LANCET HIV, 2017, 4 (05): : E195 - E204
[25] A Review of the Efficacy and Safety of Genvoya (R) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection
Angione, Sara A.
Cherian, Sibyl M.
Ozdener, Ayse Elif
JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 216 - 221
[26] Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Post, Frank A.
Tebas, Pablo
Clarke, Amanda
Cotte, Laurent
Short, William R.
Abram, Michael E.
Jiang, Shuping
Cheng, Andrew
Das, Moupali
Fordyce, Marshall W.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) : 180 - 184
[27] Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders
Havens, Joshua P.
Bares, Sara H.
Lyden, Elizabeth
Fadul, Nada
Swindells, Susan
OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
[28] Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results
Gallant, Joel E.
Koenig, Ellen
Andrade-Villanueva, Jaime
Chetchotisakd, Ploenchan
DeJesus, Edwin
Antunes, Francisco
Arasteh, Keikawus
Moyle, Graeme
Rizzardini, Giuliano
Fehr, Jan
Liu, Yapei
Zhong, Lijie
Callebaut, Christian
Szwarcberg, Javier
Rhee, Martin S.
Cheng, Andrew K.
JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (01) : 32 - 39
[29] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Cohen, Calvin
Wohl, David
Arribas, Jose R.
Henry, Keith
Van Lunzen, Jan
Bloch, Mark
Towner, William
Wilkins, Edmund
Ebrahimi, Ramin
Porter, Danielle
White, Kirsten
Walker, Ivan
Chuck, Susan
De-Oertel, Shampa
Fralich, Todd
AIDS, 2014, 28 (07) : 989 - 997
[30] Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
Cahn, Pedro
Sax, Paul E.
Squires, Kathleen
Molina, Jean-Michel
Ratanasuwan, Winai
Rassool, Mohammed
Bloch, Mark
Xu, Xia
Zhou, Yan
Homony, Brenda
Hepler, Deborah
Teppler, Hedy
Hanna, George J.
Nguyen, Bach-Yen
Greaves, Wayne
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (05) : 589 - 598

← 1 2 3 4 5 →